These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29554579)

  • 1. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Ricciardi D; Tedeschi G
    Muscle Nerve; 2019 Dec; 60(6):662-667. PubMed ID: 31415091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
    Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of intravenous immunoglobulin in CIDP.
    Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
    Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy.
    Clerici AM; Nobile-Orazio E; Mauri M; Squellati FS; Bono GG
    BMC Neurol; 2017 Jul; 17(1):127. PubMed ID: 28668085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
    Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK
    Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
    J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages.
    Grüter T; Motte J; Bulut Y; Kordes A; Athanasopoulos D; Fels M; Schneider-Gold C; Gold R; Fisse AL; Pitarokoili K
    Eur J Neurol; 2022 Feb; 29(2):583-592. PubMed ID: 34687104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins.
    Lawley A; Seri S; Rajabally YA
    Clin Neurophysiol; 2019 Oct; 130(10):1743-1749. PubMed ID: 31400577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Alcantara M; Hartung HP; Lawo JP; Durn BL; Mielke O; Bril V
    Clin Neurophysiol; 2021 Sep; 132(9):2184-2190. PubMed ID: 34293528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.
    Merkies IS; van Nes SI; Hanna K; Hughes RA; Deng C
    J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1194-9. PubMed ID: 20647554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
    Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
    Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.